Clinical Study of Ningmitai Capsule on Promoting the Passage of Residual Fragments After Ureteroscopic Lithotripsy
Status:
Completed
Trial end date:
2019-04-25
Target enrollment:
Participant gender:
Summary
Objective: To observe the effect of Ningmitai capsule on ureteral calculi after lithotripsy
and evaluate the safety of treatment.
Study Design: A multicenter, prospective, randomized, controlled clinical study design was
adopted
Interventions:
control group: Give antibiotics or diclofenac sodium suppository as needed. Ningmitai group:
Oral Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38
g/capsule, 4 capsules each time, 3 times a day.
combination group (Ningmitai plus tamsulosin).: Tamsulosin capsules, 0.2 mg/capsule, one
capsule each time, once a day, were taken on the basis of Ningmitai group.